← Back

Wire · opportunities

Pfizer steps into in vivo CAR T space with $2.6B licensing deal

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at drugdiscoverynews.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Pfizer has entered an exclusive $2.6 billion licensing deal with Starna Therapeutics for three in vivo pre-IND CAR-T autoimmune programs, marking Pfizer's first move into the in vivo CAR-T space amid upcoming patent expirations.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You should now consider in vivo CAR-T as a viable autoimmune treatment path, as Pfizer's entry signals growing commercial validation and upcoming market openings in biotech therapies. Starna's technology could offer new partnership or competitive opportunities in CAR-T for autoimmune diseases.

◆ Coverage

1 source · 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechcar-tautoimmunelicensing-dealpfoizerstarna-therapeutics